NSAIDs Stent Study

Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Aug 17, 2018

Keywords

ClinConnect Summary

The NSAIDs Stent Study is a clinical trial designed to investigate how a pain relief medication called Ketorolac affects inflammation and symptoms related to ureteral stents in patients who are having a stent placed due to kidney stones. This study aims to see if using Ketorolac can help patients feel better after the stent procedure and to evaluate how easy it is to recruit and manage participants for this kind of research.

To participate in this study, you need to be over 18 years old and planning to have a ureteral stent placed after treatment for kidney stones. However, some people may not be eligible, such as those on certain long-term pain medications or those with specific health issues like active infections or ulcers. If you join the trial, you can expect close monitoring and support throughout the process. This study is currently recruiting, and both men and women are encouraged to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Over 18 years of age and willing and able to provide informed consent
• • Patients with renal urolithiasis planning to undergo ureteral stent placement following ureteroscopic manipulation
• Exclusion Criteria:
• • Patients requiring a bilateral stone procedure.
• • Patients on a chronic non-steroidal anti-inflammatory drugs (NSAIDs) including Aspirin defined as any NSAIDs use for more than fifteen days within thirty days prior to the procedure. Exception: use of daily Aspirin 81 mg is allowed.
• • Patients on any steroid therapy.
• • Patients with prescription anti-inflammatory drugs.
• • Patients with gastrointestinal ulcers.
• • Patients with ureteral obstruction or stricture unrelated to stone disease.
• • Patients with active urinary tract infection as evidence of untreated positive urine culture obtained prior to the procedure (as part of pre-operative testing).
• • Patients with preexisting indwelling ureteral stent
• • Patients who are pregnant or lactating.
• • Patients with renal or liver impairment.
• • Patients with concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would render the patient inappropriate for enrollment.